| Patient | Fannie Lou Hamer |
|---|---|
| Date of birth | 1976-10-06 |
| Identifiers | MRN HR-ML031-SYN; SSN (made up) 000-31-2479 |
| Document date | 2026-05-04 |
| Author | Lorraine Batiste-Hill, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: blood pressure, kidney function and potassium after the new medicines, lipids, retinal photographs, and benefits. [S]
Mrs. Hamer returns six weeks after starting amlodipine-benazepril and dapagliflozin. Her home readings have come down to an average of 138/86. She has had no dizziness, cough, ankle swelling or genital itching. The potassium and creatinine check planned one to two weeks after the new medicines did not happen: the neighbor who was to drive her could not, the health center's van did not run to her road that week, and she did not want to ask again. SNAP has been approved; the energy assistance is pending. She went to the first diabetes class. She agreed today to blood tests and to retinal photographs once the camera was explained, and asked to see the pictures. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 138/86 |
| Missed check | Potassium and creatinine not done at one to two weeks: no ride |
| Side effects | None |
| Benefits | SNAP approved; energy assistance pending |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness or fainting |
| Respiratory | Negative | No cough |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Eyes | Positive | Reduced vision in the left eye, unchanged |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal | Two tablets with the evening meal (after one week of one tablet) | Oral route | 2026-03-09 to 2026-07-13 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-23 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 2026-03-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 91.8 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 34.6 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 78 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.6 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-05-04 | Cholesterol [Mass/volume] in Serum or Plasma | 154 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 80 | mg/dL | Goal below 70 mg/dL with diabetes and kidney disease | Normal | S |
| 2026-05-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=50 mg/dL | Low | S |
| 2026-05-04 | Triglyceride [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Consent and chaperone | Blood draw, retinal photographs and examination explained and agreed; female nurse present |
| General | Well; blood pressure 136/84, pulse 78; weight 91.8 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Eyes | Retinal photographs without dilating drops: no diabetic retinopathy in either eye; old scarring in the left eye consistent with her past injury |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later life | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes is documented only at the end of her life. |
| Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks; the old kidney injury is documented. |
| Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later life | active | confirmed | I12.9 | S — Synthetic modern diagnosis; hypertension is reported only at the end of her life. |
| Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contribute | active | confirmed | N18.2 | S — Synthetic kidney findings anchored to the documented permanent kidney damage. |
| Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention) | active | confirmed | E11.22 | S — Synthetic modern coding. |
| Food insecurity: food runs out before the end of most months | active | confirmed | Z59.41 | S — Synthetic social need found on the screen. |
| Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrange | active | confirmed | Z59.82 | S — Synthetic social need anchored to her rural Delta home. |
| Hyperlipidemia: LDL 146 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Consent and chaperone for every examination, test and procedure | Every visit | Completed today | Blood draw, photographs and examination explained and agreed; she asked to see her retinal pictures and they were shown to her |
| Examination | Clinic blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 136/84 |
| Self-management | Home blood pressure readings | Seven days to confirm the diagnosis; then twice a week, and daily for a week after any change | Completed today | Average 138/86 |
| Examination | Weight and BMI | Every visit | Completed today | 91.8 kg |
| Laboratory | Potassium, creatinine and eGFR | One to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes) | Deferred | Missed: the check planned one to two weeks after starting benazepril and dapagliflozin was not done because she had no ride. No harm judging by today's results (potassium 4.7 mmol/L; creatinine 1.04 mg/dL, eGFR 66, a fall of under 10%). Corrective action: checks scheduled on her clinic days with rides booked in advance, and a home blood draw when no ride can be found |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 80, total cholesterol 154, HDL 46, triglycerides 142 mg/dL |
| Laboratory | ALT, AST and FIB-4 | At baseline, then yearly | Completed today | ALT 26 U/L on atorvastatin; FIB-4 at intake low (0.82) |
| Imaging | Diabetic eye examination (retinal photographs) | At diagnosis, then every 1 to 2 years if no retinopathy | Completed today | No diabetic retinopathy; old left-eye scarring |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and cost | Every visit | Completed today | No dizziness, cough, swelling or genital itching; all medicines affordable through the discount pharmacy |
| Medication safety | Hepatitis B dose 2 | One month after dose 1 | Completed today | Given after she agreed; series complete |
| Self-management | Diabetes self-management education and support | At diagnosis, then yearly and when needs change | Completed today | First group class attended |
| Survey | Social needs screen (AHC-HRSN) and resources | At intake, then every few months while needs are open | Up to date | SNAP approved; energy assistance pending; transportation the open need |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: Introduction and Methodology: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026); Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014); Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026); The Accountable Health Communities Health-Related Social Needs Screening Tool (2017); Adult Immunization Schedule by Age (2026)
Follow-up: Home readings by phone in four weeks. Review in two months with the A1c, urine albumin, potassium and creatinine, the PHQ-9 and the social needs screen, with the ride booked today. Next scheduled visit 2026-07-13: four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose. [S]